The role of gut microflora dysbiosis in clinical manifestation of patients with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Downloads
Background and aim: The aim of this study was to evaluate the role of gut microbiota with wide variety of clinical manifestations of patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Methods: The study enrolled 133 cases of patients with NAFLD/NASH who were diagnosed at Enmedic Clinic, Tbilisi/Georgia and carried out between May 2017 and May 2021. Patients were 21-65 years of age attending our clinic. Patients were diagnosed with NASH/NAFLD based on fibroscan of liver and ultrasound investigation, and additionaly for NASH with raised serum alanine aminotransferase (ALT) and aspartat aminotrasnferase (AST) levels greater than upper limit of normal (40 IU/ ml). Trial profile of patients is shown on figure 1.
10 patients loss follow up The 123 patients were divided into three groups. Group A (61 patients) was diagnosed with NAFLD, the 42 patients of group B were diagnosed with NASH and group C (control) were 20 healthy volunteers.
Results: Family Enterobacteriaceae, family Lactobacillaceae, and genus Bacteroides like Streptococcus were increased in patients with NAFLD/NASH compared with controls, also uncultured Clostridiales as well as entero-hemolytic Escherichia Coli were increased, whereas genus Faecalibacterium, and genus Bifidobacterium as well as hemolytic Enterococcus faecalis were decreased in patients with NAFLD/NASH. Significant loss of beneficial bacteria for intestinal barrier function like Faecalibacterium was observed. The diversity of the microbiota was decreased in patients compared with controls.
Conclusions: This study found that the gut microbiota play a large role in the development of NAFLD/NASH. NAFLD developed in the initially in patients with significant dysbiosis. It suggests also that the gut microbiome correction may be beneficial for the treatment of patients with NAFLD/NASH.
Downloads
Alves CC, Waitzberg DL, de Andrade LS, Dos Santos Aguiar L, Reis MB, Guanabara CC, Júnior OA, Ribeiro DA, Sala P. Prebiotic and synbiotic modifications of beta oxidation and lipogenic gene expression after experimental hypercholesterolemia in rat liver. Front Microbiol. 2017;8:2010. doi: 10.3389/fmicb.2017.02010.
Azad MB, Bridgman SL, Becker AB, Kozyrskyj AL. Infant antibiotic exposure and the development of childhood overweight and central adiposity. Int J Obes (Lond) 2014;38:1290–1298. doi: 10.1038/ijo.2014.119.
Baddini Feitoza A, Fernandes Pereira A, Ferreira da Costa N, Gonçalves Ribeiro B. Conjugated linoleic acid (CLA): Effect modulation of body composition and lipid profile. Nutr Hosp. 2009;24:422–428.
Baffy G. Potential mechanisms linking gut microbiota and portal hypertension. Liver Int. 2019;39:598–609. doi: 10.1111/liv.13986.
Belei O, Olariu L, Dobrescu A, Marcovici T, Marginean O. The relationship between non-alcoholic fatty liver disease and small intestinal bacterial overgrowth among overweight and obese children and adolescents. J Pediatr Endocrinol Metab. 2017;30:1161–1168. doi: 10.1515/jpem-2017-0252.
Birerdinc A, Younossi ZM. Epigenome-wide association studies provide insight into the pathogenesis of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Ann Hepatol. 2018;17:11–13. doi: 10.5604/01.3001.0010.7530.
Borrelli A, Bonelli P, Tuccillo FM, Goldfine ID, Evans JL, Buonaguro FM, Mancini A. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. Redox Biol. 2018;15:467–479. doi: 10.1016/j.redox.2018.01.009.
Boulangé CL, Neves AL, Chilloux J, Nicholson JK, Dumas ME. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 2016;8:42. doi: 10.1186/s13073-016-0303-2.
Cho I, Yamanishi S, Cox L, Methé BA, Zavadil J, Li K, Gao Z, Mahana D, Raju K, Teitler I, et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature. 2012;488:621–626. doi: 10.1038/nature11400.
Compare D, Coccoli P, Rocco A, Nardone OM, De Maria S, Carteni M, Nardone G. Gut-liver axis: The impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2012;22:471–476. doi: 10.1016/j.numecd.2012.02.007.
Cruz-Ramón V, Chinchilla-López P, Ramírez-Pérez O, Méndez-Sánchez N. Bile acids in nonalcoholic fatty liver disease: New concepts and therapeutic advances. Ann Hepatol. 2017;16(Suppl 1: S3-S105):S58–S67. doi: 10.5604/01.3001.0010.5498.
Day CP, James OF. Steatohepatitis: A tale of two ‘hits’? Gastroenterology. 1998;114:842–845. doi: 10.1016/S0016-5085(98)70599-2.
Del Campo JA, Gallego-Durán R, Gallego P, Grande L. Genetic and epigenetic regulation in nonalcoholic fatty liver disease (NAFLD) Int J Mol Sci. 2018;19:E911. doi: 10.3390/ijms19030911.
Devillard E, McIntosh FM, Duncan SH, Wallace RJ. Metabolism of linoleic acid by human gut bacteria: Different routes for biosynthesis of conjugated linoleic acid. J Bacteriol. 2007;189:2566–2570. doi: 10.1128/JB.01359-06.
European Association for the Study of the Liver (EASL)1; European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO), corp-author EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–1402. doi: 10.1016/j.jhep.2015.11.004.
Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients. 2014;6:5583–5599. doi: 10.3390/nu6125583.
Fukunishi S, Sujishi T, Takeshita A, Ohama H, Tsuchimoto Y, Asai A, Tsuda Y, Higuchi K. Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats. J Clin Biochem Nutr. 2014;54:39–44. doi: 10.3164/jcbn.13-49.
Ghoshal UC, Baba CS, Ghoshal U, Alexander G, Misra A, Saraswat VA, Choudhuri G. Low-grade small intestinal bacterial overgrowth is common in patients with non-alcoholic steatohepatitis on quantitative jejunal aspirate culture. Indian J Gastroenterol. 2017;36:390–399. doi: 10.1007/s12664-017-0797-6.
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321. doi: 10.1002/hep.20701.
Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13:412–425. doi: 10.1038/nrgastro.2016.85. [PubMed] [CrossRef] [Google Scholar]
Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: Human gut microbes associated with obesity. Nature. 2006;444:1022–1023. doi: 10.1038/4441022a.
Li CY, Dempsey JL, Wang D, Lee S, Weigel KM, Fei Q, Bhatt DK, Prasad B, Raftery D, Gu H, Cui JY. PBDEs altered gut microbiome and bile acid homeostasis in Male C57BL/6 mice. Drug Metab Dispos. 2018;46:1226–1240. doi: 10.1124/dmd.118.081547.
Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, Corthesy I, Corthesy I, Macé K, Chou CJ. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J. 2008;22:2416–2426. doi: 10.1096/fj.07-102723.
Mokhtari Z, Gibson DL, Hekmatdoost A. Nonalcoholic fatty liver disease, the gut microbiome, and diet. Adv Nutr. 2017;8:240–252. doi: 10.3945/an.116.013151.
Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology. 2009;136:65–80. doi: 10.1053/j.gastro.2008.10.080.
Park JS, Seo JH, Youn HS. Gut microbiota and clinical disease: Obesity and nonalcoholic Fatty liver disease. Pediatr Gastroenterol Hepatol Nutr. 2013;16:22–27. doi: 10.5223/pghn.2013.16.1.22.
Poeta M, Pierri L, Vajro P. Gut-liver axis derangement in non-alcoholic fatty liver disease. Children (Basel) 2017;4:E66.
Rafiei R, Bemanian M, Rafiei F, Bahrami M, Fooladi L, Ebrahimi G, Hemmat A, Torabi Z. Liver disease symptoms in non-alcoholic fatty liver disease and small intestinal bacterial overgrowth. Rom J Intern Med. 2018;56:85–89.
Raso GM, Simeoli R, Iacono A, Santoro A, Amero P, Paciello O, Russo R, D'Agostino G, Di Costanzo M, Canani RB, et al. Effects of a Lactobacillus paracasei B21060 based synbiotic on steatosis, insulin signaling and toll-like receptor expression in rats fed a high-fat diet. J Nutr Biochem. 2014;25:81–90. doi: 10.1016/j.jnutbio.2013.09.006.
Rinella ME. Nonalcoholic fatty liver disease: A systematic review. JAMA. 2015;313:2263–2273. doi: 10.1001/jama.2015.5370.
Santacruz A, Collado MC, García-Valdés L, Segura MT, Martín-Lagos JA, Anjos T, Martí-Romero M, Lopez RM, Florido J, Sanz Y. Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women. Br J Nutr. 2010;104:83–92. doi: 10.1017/S0007114510000176.
Shanab AA, Scully P, Crosbie O, Buckley M, O'Mahony L, Shanahan F, Gazareen S, Murphy E, Quigley EM. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: Association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci. 2011;56:1524–1534. doi: 10.1007/s10620-010-1447-3.
Shin NR, Whon TW, Bae JW. Proteobacteria: Microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 2015;33:496–503. doi: 10.1016/j.tibtech.2015.06.011.
Simeone JC, Bae JP, Hoogwerf BJ, Li Q, Haupt A, Ali AK, Boardman MK, Nordstrom BL. Clinical course of nonalcoholic fatty liver disease: An assessment of severity, progression, and outcomes. Clin Epidemiol. 2017;9:679–688. doi: 10.2147/CLEP.S144368.
Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology. 2010;52:1836–1846. doi: 10.1002/hep.24001.
Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: Pathology and pathogenesis. Annu Rev Pathol. 2010;5:145–171. doi: 10.1146/annurev-pathol-121808-102132.
Ursell LK, Clemente JC, Rideout JR, Gevers D, Caporaso JG, Knight R. The interpersonal and intrapersonal diversity of human-associated microbiota in key body sites. J Allergy Clin Immunol. 2012;129:1204–1208. doi: 10.1016/j.jaci.2012.03.010.
Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143:913–916.e7. doi: 10.1053/j.gastro.2012.06.031.
Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut. 2001;48:206–211. doi: 10.1136/gut.48.2.206.
Zhang C, Björkman A, Cai K, Liu G, Wang C, Li Y, Xia H, Sun L, Kristiansen K, Wang J, et al. Impact of a 3-months vegetarian diet on the gut microbiota and immune repertoire. Front Immunol. 2018;9:908. doi: 10.3389/fimmu.2018.00908.
Zhang X, Chen Y, Zhu J, Zhang M, Ho CT, Huang Q, Cao J. Metagenomics analysis of gut microbiota in a high fat diet-induced obesity mouse model fed with (−)-epigallocatechin 3-O-(3-O-Methyl) gallate (EGCG3′'Me) Mol Nutr Food Res. 2018;62:e1800274. doi: 10.1002/mnfr.201800274.
Zununi Vahed S, Moghaddas Sani H, Rahbar Saadat Y, Barzegari A, Omidi Y. Type 1 diabetes: Through the lens of human genome and metagenome interplay. Biomed Pharmacother. 2018;104:332–342. doi: 10.1016/j.biopha.2018.05.052.
Copyright (c) 2022 International Journal of Scientific Research and Management
This work is licensed under a Creative Commons Attribution 4.0 International License.
